Evaluation of a job retention program for breast cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates a job retention program aimed at helping women aged 18 to 55 who have been diagnosed with invasive breast cancer return to and maintain employment after treatment. The study involves individual semi-directive interviews and focus groups to gather insights on the challenges faced by these women, including the impact of cancer and its treatment on their ability to work. By identifying barriers and facilitators to job retention, the program seeks to improve social participation and financial independence for breast cancer survivors.

Why it matters

Who can join: the full rules

* Inclusion Criteria concerning FASTRACS-RCT participants (groupe 1) \* :

  * Patients included in the intervention arm of the "FASTRACS-RCT" trial who have completed their participation in the trial.
  * Woman aged between 18 and 55.
  * With a diagnosis of invasive breast carcinoma of stage cTNM or pTNM stage I to III (UICC 8th edition), confirmed on histological examination.
  * Treated by intravenous cytotoxic chemotherapy in an adjuvant or neoadjuvant situation.
  * Breast surgery +/- of the axillary area, carried out within 3 months preceding the start of adjuvant chemotherapy, or scheduled after neoadjuvant chemotherapy +/- radiotherapy.
  * In salaried employment at the time of diagnosis (permanent or temporary contract, interim assignment, civil servant).
  * Affiliated to a French social security scheme.
  * Reading, understanding, and writing the French language.
  * Followed in one of the investigating centers.
  * Not opposing the collection data.
* Inclusion Criteria \* :

  * Persons declared by the patients for the study of the trajectories and only if their agreement is obtained for each person concerned (general practitioner, occupational physician, personnel of the resource center fort occupational and environmental pathologies (CRPPE), colleagues and hierarchy in the company and any key person identified by the patient who participated in the recovery process using the intervention tools).(groupe 2)
  * Participants in discussion groups independent of trajectories (oncologists, clinical research associates, general practitioners, occupational health teams and CRPPE staff). (Groupe 3)
  * For all categories of participants, it is necessary to be of legal age, to be able to read, understand and speak French.
* Exclusion Criteria concerning FASTRACS-RCT participants (groupe 1)\* :

  * In situ carcinoma.
  * Distant metastases.
  * History or co-existence of another primary cancer (apart from a basal cell cancer of the skin and/or non-mammary cancer in complete remission for more than 5 years).
  * Recurrence or second breast cancer.
  * Without employment contract, self-employed or supported contract.
  * Cannot be followed for the duration of the study, for medical, social, family, geographical or psychological reasons.
  * Deprived of liberty by court or administrative decision.
* Exclusion Criteria \* :

  * No exclusion criteria concern participants related to patients (declared by patients) (groupe 2).
  * No exclusion criteria for the people delivering the intervention (focus group participants) (groupe 3).

Where it's running

• Pôle de Santé Publique des Hospices Civils de Lyon
  Lyon, France Recruiting

Study contacts

• Study coordinator: Marion LAMORT BOUCHE, MD
• Email: marion.lamort-bouche@univ-lyon1.fr
• Phone: 04 72 11 28 04

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.